Lilly CEO Gives Kudos To China SFDA Reorganization, But Hopes For More
This article was originally published in PharmAsia News
Executive Summary
A reorganized SFDA could add momentum to regulatory reform and accelerated clinical trial approval, Lilly CEO John Lechleiter said during a visit to China. The exec also discussed the recent expansion of China’s Essential Drug List and other hot topics.